Tag:
BIND Biosciences
Latest Headlines
Latest Headlines
AstraZeneca and Boston biotech unite to blast cancer with a nanotech drug
The drug giant, which is in the process of renovating its R&D wing, has hired on the crafty Cambridge, MA-based biotech Bind Therapeutics to work on a kinase inhibitor nanotech drug for treating cancer.
Resurgent Pfizer partners with Bind on new nanotech drug effort
Just a few months after inking a tie-up with Amgen, Bind Therapeutics has come back from the deal table with another marquee partner looking to use its nanoengineering platform to launch newly amped-up treatments into the clinic.
Langer's Bind Biosciences raises cash as lead cancer program heads to PhII
Bind Biosciences has landed an $8.7 million chunk of a planned $20 million raise designed to fuel the biotech's midstage study of its lead cancer drug.
Bob Langer biotech lands first big biopharma deal with Amgen
For the first time BIND Biosciences has found a large drugmaker to commit major money to collaborate on a drug with its nanomedicine platform.
Influential Russian takes a big stake in U.S. biotechs
Anatoly Chubais is one of the most influential figures in the Russian government. And he's now using his influence to invest billions of dollars in new technology through Rusnano, a move that has benefited a slate of U.S. biotechs.
Nanomedicine standout spotlights first human cancer data
Bind Biosciences has scored some initial blows against cancers in humans, providing data that back up some of the promise of its nanomedicine Bind-014 in preclinical tests.
Exclusive: MIT's Langer, Farokhzad launch combination-med biotech
Serial biotech entrepreneurs Robert Langer and Omid Farokhzad are joining up with MIT's Dr. Stephen Lippard to launch a new drug developer--Blend Therapeutics--which will concentrate on the
Russian fund leads $94.5M investment in two Langer biotechs
A pair of Boston-area biotechs focused on some cutting-edge bionanotechnology inspired by MIT's prolific Bob Langer is splitting a $94.5 million investment windfall spearheaded by RusNano, a
Roche, Novartis make MIT innovators list
MIT's Technology Review has unveiled its list of the top 50 innovators, and nine life science companies have made the list. Roche and Novartis are representing Big Pharma this year. Roche's work
Bind banks $12.4M round as lead program heads into PhI
In the beginning of the year, when Cambridge, MA-based Bind Biosciences took the wraps off an $11 million round , the biotech company aroused considerable interest in the venture community. That
